Ectopic pregnancy nursing: β-hCG discriminatory zone, methotrexate, and rupture signs

Ectopic pregnancy occurs when a fertilized egg implants outside the uterine cavity – most often in a fallopian tube. CDC data put it at approximately 2% of reported US pregnancies (ACOG Practice Bulletin 193), and it remains the leading cause of pregnancy-related death in the first trimester, primarily from hemorrhagic shock following tubal rupture (Barnhart 2009). In CDC’s Pregnancy Mortality Surveillance System for 2012–2019, ruptured ectopic pregnancy was the most frequent cause of hemorrhage-related pregnancy deaths, at 22.9% of the 606 hemorrhage deaths recorded (Hollier 2024). For nursing students, ectopic pregnancy is a high-yield topic because it demands rapid pattern recognition, serial assessment skills, and clear patient education – all of which appear regularly on NCLEX.

This reference covers the full clinical picture: pathophysiology, risk stratification, diagnostic workup including β-hCG interpretation, medical versus surgical management, and the nursing priorities that protect patients from life-threatening complications.

Pathophysiology

Under normal circumstances, a fertilized egg travels through the fallopian tube over approximately 4–5 days, propelled by ciliary action and smooth-muscle peristalsis, before implanting in the uterine endometrium. When that transport is delayed or interrupted – by tubal scarring, anatomical distortion, or impaired ciliary function – implantation can occur before the egg reaches the uterus.

The fallopian tube lacks the structural adaptability of the uterus. As the trophoblast invades the thin tubal wall and the embryo grows, the tube stretches. Without intervention, the tubal wall eventually erodes. Rupture releases blood directly into the peritoneal cavity, triggering rapid hemorrhage. Because the peritoneal space can accommodate large volumes before hemodynamic instability becomes obvious, patients can deteriorate quickly once the threshold is crossed.

Blood pooling beneath the diaphragm causes referred shoulder pain (Kehr’s sign) – a finding that should prompt immediate escalation even in a patient who appears hemodynamically stable. The relationship between abdominal findings and peritoneal irritation is covered in more depth in the OB nursing reference.

Risk factors

Understanding risk factors allows nurses to identify at-risk patients early – before symptoms escalate to rupture. Risk factors broadly map to anything that impairs normal ovum transport or creates anatomical distortion. Keep two caveats in mind: about half of patients diagnosed with ectopic pregnancy have no known risk factor, and oral contraceptive use, emergency contraception failure, prior induced abortion, pregnancy loss, and cesarean birth have not been linked to higher risk (ACOG PB 193; Bouyer 2003). Every sexually active patient of reproductive age with abdominal pain or vaginal bleeding should have a pregnancy test, whatever contraception they report.

Clinical presentation

Classic triad

The textbook presentation combines three findings:

1. Amenorrhea – Many patients have missed one menstrual period. A positive pregnancy test is expected, though very early ectopics may have low β-hCG levels.
2. Unilateral pelvic pain – Initially crampy and intermittent; becomes sharp and severe with rupture. Diaphragmatic irritation from hemoperitoneum causes ipsilateral or bilateral shoulder pain (Kehr’s sign).
3. Abnormal vaginal bleeding – Typically light, dark, and irregular (“spotting”). Heavy flow is unusual and should prompt consideration of an intrauterine source such as placenta previa or abruption.

Unruptured vs. ruptured presentation

The clinical picture shifts dramatically at the moment of tubal rupture:

Unruptured ectopic: Mild unilateral pain, possible vaginal spotting, hemodynamically stable. Patient may walk into the ED with vague symptoms. This is the window for medical management.

Ruptured ectopic: Sudden onset of severe abdominal pain (often described as “tearing”), signs of peritoneal irritation (rebound tenderness, guarding, rigid abdomen), referred shoulder pain, and – critically – signs of hemorrhagic shock. Recognize the shock progression: tachycardia → hypotension → pallor → diaphoresis → altered mental status. This is a surgical emergency. The hemorrhagic shock pathway overlaps with obstetric hemorrhage from other causes; see the postpartum hemorrhage nursing reference for the shared shock response framework.

Physical exam findings that increase suspicion: cervical motion tenderness on bimanual exam (the “chandelier sign”), adnexal mass or fullness, uterus smaller than expected for gestational age. An unruptured ectopic can produce few or no findings, so a normal exam does not exclude it.

Diagnosis

β-hCG trends and the discriminatory level

β-hCG (beta-human chorionic gonadotropin) is secreted by trophoblastic tissue and is central to the workup, but ACOG is explicit that serum hCG values alone should not be used to diagnose ectopic pregnancy. They have to be read alongside the history, symptoms, and ultrasound (ACOG PB 193). Two principles guide interpretation:

Minimum expected rise: The old teaching that hCG “doubles every 48 hours” overstates what a viable pregnancy must do. ACOG now uses a minimum 48-hour rise that depends on the starting value: about 49% when the initial hCG is below 1,500 mIU/mL, 40% at 1,500–3,000 mIU/mL, and 33% above 3,000 mIU/mL (Barnhart 2016). About 99% of viable intrauterine pregnancies rise faster than these thresholds, so a slower rise, a plateau, or a fall suggests an abnormal pregnancy (ectopic or early loss). The reverse does not hold: a normal-looking rise or a falling level does not rule ectopic out, and rupture can occur while hCG is falling or very low. Repeat hCG is drawn 2 days after the first value, then every 2–7 days depending on the pattern.

Discriminatory level: The hCG value above which a normal intrauterine pregnancy should be visible on transvaginal ultrasound. Older teaching used 1,500–2,000 mIU/mL. ACOG PB 193 notes that intrauterine sacs have later appeared in patients whose hCG was above those levels on an empty first scan, so if a discriminatory level is used at all it should be conservatively high (as high as 3,500 mIU/mL) to avoid interrupting a wanted intrauterine pregnancy. An empty uterus above the discriminatory level strongly suggests a nonviable pregnancy, and 50–70% of these cases prove to be ectopic. Multiple gestations run higher hCG levels, and accurate gestational dating is a better guide than any single hCG value. See the nursing lab values cheat sheet for β-hCG reference ranges by gestational week.

Serial β-hCG measurements matter more than a single value. A falling level with an empty uterus often represents a resolving early loss, but it still needs follow-up to a nonpregnant level; a rising level without visible intrauterine implantation points toward ectopic.

Transvaginal ultrasound

Transvaginal ultrasound (TVUS) is the imaging study of choice. Findings are interpreted in three categories:

• Definitive ectopic: Extrauterine gestational sac with or without cardiac activity
• Suggestive: Adnexal mass, free fluid in the cul-de-sac (hemoperitoneum), empty uterus with β-hCG above discriminatory zone
• Inconclusive: No intrauterine or extrauterine pregnancy identified (“pregnancy of unknown location”). ACOG calls this a transient state that needs a definitive diagnosis: a stable patient gets repeat ultrasound, serial hCG, or both until the location is established

Progesterone

A low serum progesterone suggests a nonviable pregnancy but cannot tell you where it is. In a meta-analysis of 26 cohort studies, a single progesterone below roughly 3.2–6 ng/mL in symptomatic patients with an inconclusive ultrasound predicted a nonviable pregnancy (intrauterine or ectopic) with 98% specificity (Verhaegen 2012). Older teaching treats levels above 25 ng/mL as reassuring and 5–25 ng/mL as indeterminate. ACOG PB 193 does not include progesterone in its diagnostic pathway, which rests on ultrasound and serial hCG.

Additional labs

CBC (to establish baseline hemoglobin/hematocrit and detect occult blood loss), blood type and Rh factor, cross-match, metabolic panel, and coagulation studies if hemorrhage is suspected.

Treatment options

Management depends on hemodynamic stability, β-hCG level, ultrasound findings, gestational size, and patient preference. For a stable patient with an unruptured ectopic, ACOG rates laparoscopic surgery and intramuscular methotrexate as safe and effective options, and the choice is made with the patient (ACOG PB 193). Surgery is required for hemodynamic instability, symptoms of an ongoing ruptured mass, or signs of intraperitoneal bleeding.

Expectant management is a third option for a small group: patients who are asymptomatic, have objective evidence of resolution (a plateau or fall in hCG), and accept the risks of rupture, hemorrhage, and emergency surgery. When the initial hCG is below 200 mIU/mL, about 88% resolve spontaneously (ACOG PB 193). The nursing role is the same surveillance and return-precaution teaching used after methotrexate.

Nursing assessment and interventions

Systematic nursing care for ectopic pregnancy centers on five priorities.

1. Hemodynamic monitoring and hemorrhagic shock prevention

Establish continuous vital sign monitoring from the moment ectopic pregnancy is suspected. The most lethal complication is hemorrhagic shock from tubal rupture. Know the early warning signs and escalate before the patient decompensates:

• Tachycardia (HR >100 bpm) is usually the earliest measurable sign of hypovolemia, though young, healthy patients can compensate with a near-normal heart rate
• Orthostatic hypotension precedes supine hypotension – check lying and standing if patient is stable enough
• Narrowing pulse pressure signals increased peripheral vascular resistance in compensation
• Decreasing urine output (<0.5 mL/kg/hr) reflects renal hypoperfusion
• Sudden increase in abdominal or shoulder pain in a known ectopic patient should be treated as rupture until proven otherwise

For IV access guidance in emergency management, see the IV insertion reference. Establish at minimum one large-bore peripheral IV (18-gauge or larger). Two large-bore IVs in the antecubital fossa are preferred for patients at high rupture risk.

Have type and crossmatch drawn early – before hemodynamic deterioration. If surgery is likely, confirm that crossmatched blood is available and know how to activate the unit’s massive transfusion protocol. The approach to shock assessment mirrors the framework in the sepsis nursing reference, with the key distinction that hemorrhagic shock has a mechanical/volume cause rather than a distributive one.

2. Pain assessment and management

Administer analgesics as ordered. Document pain character, location, and trajectory – unilateral pelvic pain that becomes bilateral or radiates to the shoulder indicates expanding hemoperitoneum and requires immediate provider notification.

Avoid masking pain in a way that delays recognition of rupture. Reassess pain frequently (every 30–60 minutes in the unstable patient).

3. Rh factor and RhoGAM administration

Rh-negative patients who experience trophoblastic loss can become sensitized if fetal blood is Rh-positive. Sensitization has no effect on the current pregnancy but causes hemolytic disease of the fetus/newborn (HDFN) in subsequent Rh-positive pregnancies.

Guidance on early pregnancy loss changed in 2024, and the major bodies no longer agree. Older textbooks teach RhIg for every Rh-negative patient after any first-trimester pregnancy event. The current picture looks like this:

• ACOG Clinical Practice Update (published September 2024, in print December 2024): for patients under 12 0/7 weeks who are undergoing abortion or experiencing pregnancy loss, ACOG suggests forgoing routine Rh testing and RhIg, while allowing both on an individual basis through shared decision-making. The update revises ACOG’s guidance on medication abortion, early pregnancy loss, and Rh D alloimmunization; it does not name ectopic pregnancy or amend the ectopic pregnancy bulletin (PB 193).
• SOGC Guideline No. 448 (Canada, 2024): the one guideline here that addresses ectopic pregnancy by gestational age. It recommends not giving RhIg for ectopic pregnancy before 8 weeks and suggests not giving it at 8–12 weeks, with RhIg an option for risk-averse patients.
• NICE NG126 (UK): offers anti-D 250 IU (50 mcg) to Rh-negative patients who have a surgical procedure for ectopic pregnancy, and does not offer it after medical management alone.
• SMFM (2024): recommends offering Rh testing and RhIg for spontaneous and induced abortion before 12 weeks where this is logistically and financially feasible and does not hinder access to care.

The rationale for the shift is evidence that fetal red-cell exposure before 12 weeks is very small, so alloimmunization risk is very low. Where RhIg is given, the timing rule is unchanged: within 72 hours of the event. First-trimester dosing is 50 mcg IM, although many facilities stock only the 300 mcg dose and use it.

For nursing practice, the durable points are that Rh status still belongs in the blood work for any patient who may go to surgery, and that giving or withholding RhIg after an ectopic pregnancy is now a prescriber and institutional-protocol decision. NCLEX question banks lag guideline changes, so expect legacy items that still treat RhIg as mandatory after every ectopic pregnancy.

4. Emotional and psychosocial support

Ectopic pregnancy is a pregnancy loss – often the first pregnancy the patient has known about, often wanted. The grief response is real and may be complicated by the life-threatening nature of the event, the need for rapid decision-making, and the implications for future fertility (particularly after salpingectomy).

Acknowledge the loss explicitly. Avoid language that focuses only on the clinical problem (“the tube”) and omits the pregnancy. Provide information about grief support resources and community organizations. Ensure a follow-up plan includes emotional as well as physical check-ins.

5. Pre-operative preparation (if surgical management indicated)

• Confirm NPO status and duration
• Obtain IV access, type and crossmatch, consent
• Insert Foley catheter as ordered
• Remove jewelry, prepare surgical site
• Confirm medication reconciliation – note any anticoagulants, NSAIDs, or supplements
• Communicate Rh status to surgical team

Methotrexate post-discharge teaching

Patients discharged on methotrexate require detailed education. Non-compliance with restrictions can reduce treatment efficacy or mask the signs of rupture. Use the table below as the basis for discharge teaching.

Separation pain: Warn patients that abdominal pain is common after methotrexate, typically 2–3 days after the injection (ACOG PB 193), and some patients describe it later in the first week. This “separation pain” is thought to reflect the drug’s effect on trophoblastic tissue. Acetaminophen is the usual analgesic, because NSAIDs and opioids are avoided during therapy. Without signs of rupture, providers manage it expectantly by checking hemoglobin and intraperitoneal fluid on ultrasound. Vaginal spotting is also expected. Pain that escalates beyond what acetaminophen controls, or that is accompanied by shoulder pain or hemodynamic symptoms, requires emergency evaluation.

NCLEX tips

The following are the highest-yield points for NCLEX preparation on ectopic pregnancy:

1. The classic triad is your first clinical anchor. Amenorrhea + unilateral pelvic pain + abnormal vaginal bleeding = ectopic pregnancy until proven otherwise. On a NCLEX stem, any pregnant patient presenting with these three findings should trigger ectopic pregnancy as your primary concern.

2. Shoulder pain = hemoperitoneum. Referred shoulder pain (Kehr’s sign) is caused by blood irritating the diaphragm. On NCLEX, if a pregnant patient mentions shoulder pain alongside abdominal pain, the answer almost always involves recognizing rupture and escalating to immediate surgical intervention.

3. Rho(D) immune globulin – know both the legacy rule and the 2024 change. Question banks still test the older teaching that RhIg is mandatory for any Rh-negative patient after a trophoblastic event, given within 72 hours. ACOG’s 2024 update suggests forgoing routine Rh testing and prophylaxis for abortion and pregnancy loss before 12 0/7 weeks, Canada’s SOGC recommends against RhIg for ectopic pregnancy before 8 weeks, and NICE still gives anti-D after surgical management. On an exam, answer from the order in the stem; in practice, follow the prescriber and unit protocol. The 72-hour window still governs whenever RhIg is given.

4. Methotrexate contraindications are tested frequently. The most commonly tested absolute contraindications are: viable intrauterine pregnancy, renal impairment, hepatic disease, immunodeficiency, blood dyscrasias, active peptic ulcer disease, and breastfeeding. A question showing a patient with elevated creatinine or liver enzymes being offered methotrexate should be flagged as inappropriate. Distinguish these from the relative contraindications – high β-hCG, embryonic cardiac activity, large ectopic mass – which lower success rates rather than ruling treatment out.

5. Methotrexate restrictions – the why matters. NCLEX tests understanding, not just recall. Know why folic acid is avoided (it antagonizes the drug’s mechanism), why NSAIDs are avoided (they may reduce efficacy and they slow methotrexate clearance), why opioids and alcohol are avoided (they can mask rupture pain), and why a new pregnancy is delayed (methotrexate is teratogenic).

6. β-hCG above the discriminatory level + empty uterus = suspect ectopic and keep evaluating. Many question banks still use 1,500–2,000 mIU/mL; ACOG now says any discriminatory level should be set conservatively high (as high as 3,500 mIU/mL) and that hCG alone never makes the diagnosis. A stem with a high hCG and no intrauterine pregnancy on ultrasound is testing whether you recognize a possible ectopic that needs serial hCG, repeat ultrasound, and close monitoring.

7. Separation pain vs. rupture – distinguish them. Mild abdominal pain a few days after methotrexate (typically 2–3 days) is expected separation pain, usually treated with acetaminophen. Severe pain, shoulder pain, or hemodynamic changes during this same window = rupture. NCLEX may present both and ask which patient requires immediate intervention.

8. Tachycardia is the first sign of hemorrhagic shock. In any question about a patient with ectopic pregnancy, a heart rate of 110 bpm with normal blood pressure should be treated as early hemorrhagic shock – not reassurance that the patient is stable.

Related resources

For broader obstetric nursing context, the OB nursing reference covers the full antepartum and intrapartum spectrum including physiological changes of pregnancy and obstetric emergencies.

Ectopic pregnancy is one of several conditions on the antepartum bleeding differential. The placenta previa and abruption nursing reference covers the other major causes of antepartum hemorrhage and the nursing distinctions between them.

Hemorrhagic shock management principles – including volume resuscitation sequencing and shock staging – are covered in depth in the postpartum hemorrhage nursing reference.

When interpreting serial β-hCG values or reviewing lab thresholds for diagnosis, the nursing lab values cheat sheet provides a quick reference for normal ranges and clinically significant thresholds.

References

[1] Barnhart KT. Clinical practice. Ectopic pregnancy. N Engl J Med. 2009;361(4):379–387. doi:10.1056/NEJMcp0810384

[2] American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 193: Tubal Ectopic Pregnancy. Obstet Gynecol. 2018;131(3):e91–e103 (reaffirmed 2025). doi:10.1097/AOG.0000000000002560

[3] Barnhart KT, Gosman G, Ashby R, Sammel M. The medical management of ectopic pregnancy: a meta-analysis comparing “single dose” and “multidose” regimens. Obstet Gynecol. 2003;101(4):778–784. doi:10.1016/s0029-7844(02)03158-7

[4] Lipscomb GH, Stovall TG, Ling FW. Nonsurgical treatment of ectopic pregnancy. N Engl J Med. 2000;343(18):1325–1329. doi:10.1056/NEJM200011023431807

[5] Mol F, van Mello NM, Strandell A, et al. Salpingotomy versus salpingectomy in women with tubal pregnancy (ESEP study): an open-label, multicentre, randomised controlled trial. Lancet. 2014;383(9927):1483–1489. doi:10.1016/S0140-6736(14)60123-9

[6] Seeber BE, Barnhart KT. Suspected ectopic pregnancy. Obstet Gynecol. 2006;107(2 Pt 1):399–413. doi:10.1097/01.AOG.0000198632.15229.be

[7] Kirk E, Bottomley C, Bourne T. Diagnosing ectopic pregnancy and current concepts in the management of pregnancy of unknown location. Hum Reprod Update. 2014;20(2):250–261. doi:10.1093/humupd/dmt047

[8] Centers for Disease Control and Prevention. Ectopic pregnancy – United States, 1990–1992. MMWR Morb Mortal Wkly Rep. 1995;44(3):46–48.

[9] Sivalingam VN, Duncan WC, Kirk E, Shephard LA, Horne AW. Diagnosis and management of ectopic pregnancy. J Fam Plann Reprod Health Care. 2011;37(4):231–240. doi:10.1136/jfprhc-2011-0073

[10] Creanga AA, Syverson C, Seed K, Callaghan WM. Pregnancy-related mortality in the United States, 2011–2013. Obstet Gynecol. 2017;130(2):366–373. doi:10.1097/AOG.0000000000002114

[11] National Institute for Health and Care Excellence. Ectopic pregnancy and miscarriage: diagnosis and initial management (NG126). NICE; 2019 (updated 2023), including anti-D recommendations. https://www.nice.org.uk/guidance/ng126

[12] Farquhar CM. Ectopic pregnancy. Lancet. 2005;366(9485):583–591. doi:10.1016/S0140-6736(05)67103-6

[13] Bouyer J, Coste J, Shojaei T, et al. Risk factors for ectopic pregnancy: a comprehensive analysis based on a large case-control, population-based study in France. Am J Epidemiol. 2003;157(3):185–194. doi:10.1093/aje/kwf190

[14] Tulandi T, Saleh A. Surgical management of ectopic pregnancy. Clin Obstet Gynecol. 1999;42(1):31–38. doi:10.1097/00003081-199903000-00007

[15] Practice Committee of American Society for Reproductive Medicine. Medical treatment of ectopic pregnancy: a committee opinion. Fertil Steril. 2013;100(3):638–644. doi:10.1016/j.fertnstert.2013.06.013

[16] American College of Obstetricians and Gynecologists. ACOG Clinical Practice Update: Rh D immune globulin administration after abortion or pregnancy loss at less than 12 weeks of gestation (updates PB 181, 200, and 225). Obstet Gynecol. 2024;144(6):e140–e143. doi:10.1097/AOG.0000000000005733

[17] Prabhu M, Louis JM, Kuller JA; Society for Maternal-Fetal Medicine Publications Committee. Society for Maternal-Fetal Medicine Statement: RhD immune globulin after spontaneous or induced abortion at less than 12 weeks of gestation. Am J Obstet Gynecol. 2024;230(5):B2–B5. doi:10.1016/j.ajog.2024.02.288

[18] Hollier LM, Busacker A, Njie F, Syverson C, Goodman DA. Pregnancy-related deaths due to hemorrhage: Pregnancy Mortality Surveillance System, 2012–2019. Obstet Gynecol. 2024;144(2):252–255. doi:10.1097/AOG.0000000000005628

[19] Bouyer J, Coste J, Fernandez H, Pouly JL, Job-Spira N. Sites of ectopic pregnancy: a 10 year population-based study of 1800 cases. Hum Reprod. 2002;17(12):3224–3230. doi:10.1093/humrep/17.12.3224

[20] Barnhart KT, Guo W, Cary MS, et al. Differences in serum human chorionic gonadotropin rise in early pregnancy by race and value at presentation. Obstet Gynecol. 2016;128(3):504–511. doi:10.1097/AOG.0000000000001568

[21] Menon S, Colins J, Barnhart KT. Establishing a human chorionic gonadotropin cutoff to guide methotrexate treatment of ectopic pregnancy: a systematic review. Fertil Steril. 2007;87(3):481–484. doi:10.1016/j.fertnstert.2006.10.007

[22] Verhaegen J, Gallos ID, van Mello NM, et al. Accuracy of single progesterone test to predict early pregnancy outcome in women with pain or bleeding: meta-analysis of cohort studies. BMJ. 2012;345:e6077. doi:10.1136/bmj.e6077

[23] Fung-Kee-Fung K, Wong K, Walsh J, Hamel C, Clarke G. Guideline No. 448: Prevention of Rh D alloimmunization. J Obstet Gynaecol Can. 2024;46(4):102449. doi:10.1016/j.jogc.2024.102449

[24] Stovall TG, Ling FW. Single-dose methotrexate: an expanded clinical trial. Am J Obstet Gynecol. 1993;168(6):1759–1765. doi:10.1016/0002-9378(93)90687-E

[25] Hospira, Inc. Methotrexate Injection, USP: prescribing information (Use in Specific Populations: contraception for 6 months after the last dose in females). DailyMed set ID 0d63ba29-b692-41b4-87e8-351265c8273f; revised June 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0d63ba29-b692-41b4-87e8-351265c8273f

For IV access technique and considerations in emergent situations, see the IV insertion reference.